• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Hepatic oncology. >Intermediate hepatocellular carcinoma: the role of transarterial therapy.
【24h】

Intermediate hepatocellular carcinoma: the role of transarterial therapy.

机译：中级肝细胞癌：经动脉治疗的作用。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

According to Barcelona Clinic Liver Cancer, the recommended first-line treatment for patients with intermediate stage of hepatocellular carcinoma (HCC) is transarterial chemoembolization. Patients with intermediate stage of HCC represent 20% with a 2-year survival of approximately 50%. Nowadays, transarterial therapies have proved precious in the treatment of hepatic malignancies. During the last years, there were important developments in practiced transarterial therapies and their efficacy is still controversial. The purpose of this review is to discuss in further details these transarterial therapies that have been used to treat cases of HCC.
机译：根据巴塞罗那临床肝癌，对于肝细胞癌（HCC）中期患者，推荐的一线治疗是经动脉化学栓塞。肝癌中期患者占20％，2年生存率约为50％。如今，经动脉疗法已被证明在治疗肝恶性肿瘤方面很有价值。在过去的几年中，实践中的经动脉疗法取得了重要进展，其疗效仍存在争议。这篇综述的目的是进一步详细讨论已经用于治疗HCC病例的这些经动脉疗法。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号